Announcement

Collapse
No announcement yet.

AMX0035 Safe, Effective in Slowing ALS Functional Decline, Trial Data Shows

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    AMX0035 Safe, Effective in Slowing ALS Functional Decline, Trial Data Shows

    Amylyx’s experimental oral treatment AMX0035 safely and effectively slows functional decline in amyotrophic lateral sclerosis (ALS) patients with rapidly progressing disease, according to full data from the CENTAUR Phase 2/3 trial.

    Only changes in upper limb strength were significantly different from those seen in placebo-treated patients, the data show. Meanwhile, AMX0035 was associated with a trend toward slower rates of decline in muscle strength and lung function, as well as fewer hospitalizations.- https://alsnewstoday.com/2020/09/03/...aign=OneSignal
Working...
X